NCT05818319View on ClinicalTrials.gov

Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cystic Fibrosis (CF)CFTR Gene Mutation
Interventions
OTHER

12 hours ETI pause

Patients with CF are randomly allocated to ETI pause lasting 12 hours.

OTHER

36 hours ETI pause

Patients with CF are randomly allocated to ETI pause lasting either 36 hours.

OTHER

60 hours ETI pause

Patients with CF are randomly allocated to ETI pause lasting either 60 hours.

Trial Locations (1)

8000

RECRUITING

Department of Infectious Diseases, Aarhus University Hospital, Aarhus C

All Listed Sponsors
lead

University of Aarhus

OTHER